None listed
Conditions
Interventions
Drug : Eligible patients will be randomized in three groups. In the first group, patients will be assigned to a 7-day PC-BMT therapy (Tegoprazan 50mg bid, bismuth subcitrate 300mg qid, metronidazole 2
Sponsors
Hallym University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) age >19 or <85 years 2) patients who tested positive for H. pylori 3) patients who had endoscopically confirmed gastric ulcer, duodenal ulcer (including scar), low grade gastric MALT lymphoma, gastric dysplasia or early gastric cancer, Atrophic gastritis, H. pylori gastritis 4) patients who will be compliant to study procedures 5) patients who have signed the Informed Consent 6) patients who have agreed to use acceptable contraception methods
Exclusion criteria
Exclusion criteria: 1) previous H. pylori eradication therapy 2) patients with severe concurrent disease or malignancy 3) history of gastrectomy 4) patients who used PPI, H2 blocker, Histamine H2-receptor antagonists 14 days prior to trial 5) patients who have taken bismuth-containing drugs or antibiotics within 28 days prior to trial 6) pregnant or lactating women 7) liver cirrhosis or Hepatic insufficiency 8) renal insufficiency 9) other organ cancer within 5 years 10) history of stomach operation 11) addiction to alcohol or illicit and recreational drugs 12) a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug containing rilpivirine 13) patients receiving statin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rate | — |
Secondary
| Measure | Time frame |
|---|---|
| drug compliance | — |
Countries
Korea, Republic of
Contacts
Public ContactHyun Lim
Hallym University
Outcome results
None listed